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Abstract
An effect of the widely abuse psychostimulant, methamphetamine (Meth), is blood-brain-barrier 
(BBB) disruption; however, the mechanism by which Meth causes BBB disruption remains 
unclear. Recently it has been shown that Meth produces liver damage and consequent increases in 
plasma ammonia. Ammonia can mediate oxidative stress and inflammation, both of which are 
known to cause BBB disruption. Therefore, the current studies examined the role of peripheral 
ammonia in Meth-induced disruption of BBB structure and function. A neurotoxic Meth regimen 
(10 mg/kg, ip, q 2 h, ×4) administered to rats increased plasma ammonia and active MMP-9 in the 
cortex 2 h after the last Meth injection, compared to saline treated rats. At 24 h after Meth 
treatment, decreased immunoreactivity of BBB structural proteins, occludin and claudin-5, and 
increased extravasation of 10,000 Da FITC-dextran were observed, as compared to saline controls. 
Pretreatment with lactulose (5.3 g/kg, po, q 12 h), a drug that remains in the lumen of the intestine 
and promotes ammonia excretion, prevented the Meth-induced increases in plasma ammonia. 
These results were paralleled by the prevention of decreases in BBB structural proteins, increases 
in extravasation of 10,000 Da FITC-dextran and increases in active MMP-9. The results indicate 
that Meth-induced increases in ammonia produce BBB disruption and suggest that MMP-9 
activation mediates the BBB disruption. These findings identify a novel mechanism of Meth-
induced BBB disruption that is mediated by plasma ammonia and are the first to identify a 
peripheral contribution to Meth-induced BBB disruption.
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1. Introduction
Methamphetamine (Meth) is a widely abused psychostimulant known to damage brain 
dopaminergic and serotonergic systems (Hotchkiss and Gibb, 1980; Ricaurte et al., 1980; 
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Wilson et al., 1996; Cass and Manning, 1999; Kish et al., 2009) mediated through oxidative 
stress and excitotoxicity (Wagner et al., 1985; De Vito and Wagner, 1989; Sonsalla et al., 
1991; Stephans and Yamamoto, 1994; Abekawa et al., 1996; Battaglia et al., 2002; Fukami 
et al., 2004; Staszewski and Yamamoto, 2006). One of the more recently discovered toxic 
effects of Meth is that on the blood-brain barrier (BBB) (Bowyer and Ali, 2006; Kiyatkin et 
al., 2007; Kousik et al., 2011; Martins et al., 2011) but the underlying mechanisms are 
unclear.
Meth disrupts BBB structure and function as evidenced by increases in permeability to 
endogenous IgG, Evan's blue and FITC-labeled albumin (Bowyer and Ali, 2006; Kiyatkin et 
al., 2007; Kousik et al., 2011). The increased permeability of the BBB is associated with 
alterations in tight junction proteins, the structural proteins required for proper BBB 
function. Decreased expression of these tight junction proteins including occludin, 
claudin-5, and zona occludens were observed ex vivo and is also evidenced by decreased 
transendothelial electrical resistance (TEER) in cultured brain microvascular endothelial 
cells exposed to Meth (Mahajan et al., 2008; Ramirez et al., 2009).
Meth-induced hyperthermia appears to plays a role in BBB damage since the extent of 
increases in BBB permeability correlates with brain temperature (Bowyer and Ali, 2006; 
Kiyatkin et al., 2007). The contribution of oxidative stress to Meth-induced BBB disruption 
has also been investigated. Increases in reactive oxygen species are observed in cultured 
brain microvascular endothelial cells after Meth and the antioxidant, Trolox, reduces Meth-
induced decreases in TEER in endothelial cells in culture as well as extravasation of sodium-
fluorescein in mice after Meth exposure (Ramirez et al., 2009).
Oxidative stress may also contribute to BBB damage through induction of matrix 
metalloprotease (MMP) activity. MMPs are proteases that cleave proteins of the extracellular 
matrix. More specifically, MMP-2 and MMP-9, have been associated with degradation of 
tight junction proteins in models of stroke (Yang et al., 2007). Meth also increases MMP-9 
in the hippocampus and striatum (Liu et al., 2008; Martins et al., 2011; Urrutia et al., 2013) 
and the non-specific MMP inhibitor, BB-94, prevents increases in IgG immunoreactivity in 
brain after Meth treatment (Urrutia et al., 2013), suggesting that inhibition of MMPs 
prevents Meth-induced increases in BBB permeability.
The mechanism by which Meth increases MMP-9 activity is unknown but MMP-9 
expression is increased via oxidative stress (Jian Liu and Rosenberg, 2005) and 
inflammation (Mun-Bryce and Rosenberg, 1998). Moreover, nitrosylation is known to 
cleave the inactive pro-MMP-9 to the active MMP-9 (Gu et al., 2002) and supports the 
possibility that Meth-induced oxidative stress can activate MMP-9.
Recently it has been found that Meth produces liver damage that is associated with increases 
in plasma ammonia (Halpin and Yamamoto, 2012). Increases in plasma ammonia can trigger 
a variety of responses in the brain, including hepatic encephalopathy, in which oxidative 
damage and inflammation occur (Hawkins et al., 1973; Kosenko et al., 1997b; Rodrigo et 
al., 2010; Bemeur and Butterworth, 2013). Since it is known that oxidative stress and 
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inflammation can increase MMP-9 production and activity, we hypothesized that ammonia 
may mediate the Meth-induced disruption of BBB structure and function.
2. Methods
2.1. Animals and treatments
Male Sprague Dawley rats (180–275 g, Harlan, Indianapolis, IN) were used in all 
experiments. Rats were housed 2 per cage, in clear plastic containers (45 × 24 × 20 cm), and 
allowed 4–5 days to acclimate to the animal colony before any experimentation. The 
environment in which the rats were housed was under a 12 h light/dark cycle, temperature 
(23 ± 1 °C) and humidity (40 ± 5%) controlled. Rats had ad libitum access to food and 
water. All procedures were carried out in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and approved by the University of 
Toledo Institutional Animal Care and Use Committee. Efforts were made to minimize the 
number of rats used as well as to minimize the amount of suffering each rat might endure.
Rats received Meth (10 mg/kg i.p., q. 2 h × 4) (Sigma, St. Louis, MO, Cat. M8750) or saline 
(1 mL/kg i.p., q. 2 h × 4). This dose of Meth was chosen based on previous studies that use 
this dosing regimen that illustrate long-term neuronal damage similar to what is seen in 
studies of human Meth users (McCann et al., 1998).
Rats received lactulose (Pharmaceutical Associates Inc., Greenville, SC) (5.3 g/kg) or 
vehicle (100 mg/mL galactose and 80 mg/mL lactose) (Fisher Scientific, Pittsburg, PA) via 
oral gavage every 12 h, starting 2 days before Meth treatment and continuing until the day 
before the rats were killed. The rationale for the use of lactulose is that lactulose enhances 
ammonia excretion by altering the pH of the intestinal lumen and is used clinically to treat 
the neurological symptoms of hepatic encephalopathy (Jia and Zhang, 2005; Nicaise et al., 
2008; Al Sibae and McGuire, 2009). All rats were killed by rapid decapitation 2 h after the 
end of treatment or 24 h after the start of the Meth or saline treatment.
2.2. Body temp measurements
Temperature transponders (IPTT-300 transponder, BMDS Inc., Seaford, DE) were 
subcutaneously implanted into the rats at least 2 days prior to beginning each experiment to 
allow for equilibration. This method of remote temperature monitoring minimizes stress to 
the rats produced by repeated rectal recordings. Temperatures were recorded prior to and 1 h 
after each Meth or saline injection.
2.3. Detection of plasma ammonia
Plasma was prepared by collecting trunk blood from rats following rapid decapitation in BD 
Microtainer Plasma Separation Tubes and immediately centrifuged at 10,000×g for 2 min at 
4 °C. Plasma was analyzed for ammonia on an UniCel DxC800 Synchron Clinical System 
(Beckman Coulter, Indianapolis, IN).
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2.4. Isolation of brain capillaries
Brain capillaries were isolated based on protocol by Northrop and Yamamoto (2012). 
Briefly, fresh cortical tissue was collected from rats killed by rapid decapitation and placed 
into ice-cold Hanks' Balanced Salt Solution 1× (HBSS). Samples were kept on ice or at 4 °C 
throughout the isolation procedure. Meninges and large blood vessels were removed. Tissue 
was suspended in 17.5% dextran (64–76 kDa, Sigma, St. Louis, MO) and centrifuged at 
4400g at 4 °C for 15 min to produce a pellet of capillaries. The supernatant was collected 
along with floating tissue pieces, placed into a separate tube, and centrifuged at 4400g for 15 
min at 4 °C that resulted in a second pellet containing capillaries. Pellets containing 
capillaries were re-suspended in ice-cold HBSS and filtered through 100 μm nylon mesh 
(Spectrum Laboratories, Inc., Rancho Dominguez, CA) to remove large blood vessels. The 
filtrate containing the capillaries was centrifuged at 1000g for 5 min to concentrate the 
capillaries.
2.5. Western Blots for occludin and claudin-5 and alpha-tubulin
Occludin and claudin-5 were measured in isolated capillary protein as in Northrop and 
Yamamoto (2012). Briefly, isolated capillaries, described above, were re-suspended in a urea 
buffer with protease inhibitor cocktail, at a pH of 8.0, and incubated at 4 °C for two nights to 
extract capillary proteins (Hawkins et al., 2004). Capillary protein samples were diluted with 
Novex 4× LDS sample buffer (Invitrogen, Carlsbad, CA) and boiled at 85 ° C for 10 min. 
Bradford protein assay (BioRad, Hercules, CA) was used to measure total capillary protein 
and 30 μg of protein for each sample was loaded into the wells of a NuPAGE Novex 4–12% 
Bis-Tris gel (Invitrogen, Carlsbad, CA) for electrophoresis.
Proteins were transferred onto polyvinylidene fluoride (PVDF) membranes. Membranes 
were blocked for 2 h at room temperature, with Tris-buffered saline (TBS) (10 mM Tris, 150 
mM NaCl), containing 0.5% Tween-20 and 5% non-fat powdered milk. Membranes were 
then incubated with primary antibodies (mouse anti-occludin, 1:500, (Invitrogen, Carlsbad, 
CA, Cat. 331500); mouse anti-claudin-5, 1:500, (Invitrogen, Carlsbad, CA, Cat. 352500); or 
mouse anti-α-tubulin, 1:3000, (Sigma, St. Louis, MO, Cat. T6074)) in blocking buffer for 
approximately 18 h at 4 °C. Following 3, 3 min, washes with TBS containing Tween-20 
(TBS-T) (0.5% Tween), membranes were incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies (goat anti-mouse IgG, 1:2500, (Santa Cruz, Dallas, TX) in 
blocking buffer for 1 h at room temperature. Membranes were then washed 3 times, each for 
3 min, with TBS-T.
Membranes were incubated in HyGLO enhanced chemiluminescence (ECL) (Denville 
Scientific Inc., Metuchen, NJ), for antibody detection. A Fuji LAS-4000 mini system 
(FujiFilm Corp. Life Science Division, Tokyo, Japan) was used to image chemiluminescence 
and optical density was quantified using Multi Gauge software (FujiFilm Corp. Life Science 
Division, Tokyo, Japan). Occludin and claudin-5 were normalized to the internal loading 
control, α-tubulin. Results were calculated and expressed as a percent of the control group.
Northrop et al. Page 4
Neuropharmacology. Author manuscript; available in PMC 2017 January 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2.6. FITC-dextran extravasation
Leakage of FITC-dextran from brain vasculature into parenchyma was used to determine the 
extent of BBB permeability as in Northrop and Yamamoto (2012). Briefly, 24 h after Meth 
or saline treatment, rats were anesthetized using a solution of ketamine (75 mg/kg) (Hospira, 
INC., Lake Forest, IL) and xylazine (5 mg/kg) (Lloyd Laboratories, Shenandoah, IA). The 
rat heart was exposed and heparin (35 USP units) (APP Pharmaceuticals, LLC, Schauburg, 
IL) was injected into the left ventricle. Immediately following heparin, 12 mL of FITC 
labeled 10,000 Da dextran (10 mg/mL in 0.1 M PBS) (Sigma, St. Louis, MO, Cat. FD10S) 
was infused into the left ventricle at a rate of 8 mL/min and the right atrium was severed. 
Immediately following the intracardial perfusion of FITC-dextran, brains were removed 
from the skull and fixed in 4% paraformaldehyde (PFA) for 3 days. Brains were then 
cryoprotected using 10% glycerol for 24 h and then 20% glycerol for 24 h and then flash 
frozen in 2-methylbutane over dry ice.
FITC-dextran was not flushed out of the vessels via a subsequent perfusion with PBS for 
two reasons. The first reason was to minimize stress on the vessels since excessive perfusion 
and mechanical disturbance of the vessels could cause leakage and false positive results that 
could be interpreted as increased permeability. In addition, FITC-dextran in vessels was a 
good validation of efficacious perfusions and permitted the distinct identification of 
capillaries that was be used to standardize and equate the density of capillaries across brain 
regions. This helps to ensure that FITC-dextran in the extravascular space is not confounded 
by variations in the density of capillaries.
Brains were sliced at a thickness of 50 μm using a cryostat (Microm HM 550; Thermo 
Scientific, Waltham, MA). Slices were mounted onto gelatin-coated slides and cover-slipped 
with fluoromount. Slices were imaged using a Leica SP5 confocal microscope and the 
standard Leica Applications Suite Advanced Fluorescence (LAS AF) Software. Parameters 
used to image included an excitation wavelength of 488 nm, a collection wavelength of 504–
556 nm and z-step size of 4.00 μm throughout the entire 50 μm slice. Exposure, gain and 
offset remained constant for all images. Four 20× images of regions of the cortex were 
captured per rat, from 3 brain slices, in order to analyze FITC-dextran extravasation. At the 
time of imaging and analysis, the investigator was blind to the treatment.
In order to quantify FITC-dextran extravasation, extra-capillary fluorescence in each image 
was quantified using ImageJ software. First, distinct, non-diffuse and brightly fluorescent 
areas indicative of capillaries were removed from each image by determining threshold and 
radius settings that eliminated this capillary staining from matched control slice images. This 
was done throughout the entire 50 μm slice from the z-stack images so that the FITC-dextran 
in the vessels throughout entire slice did not contribute to the measure for FITC-dextran 
extravasation. The remaining fluorescence was considered to be fluorescence associated 
with FITC-dextran that diffused into the surrounding parenchyma. The average intensity of 
this remaining fluorescence in the entire area imaged was then measured using ImageJ. The 
fluorescence values of the 12 images, from each rat, were averaged for each individual rat. 
The mean intensity of fluorescence was expressed as a percent of control and was indicative 
of FITC-dextran extravasation.
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2.7. Gelatinase zymography
The gelatinase zymography is an electrophoretic technique used to measure the artificial 
proteolytic activity of enzymes separated in polyacrylamide gels under non-reducing 
conditions. The gelatinase zymography protocol was adapted from Rosenberg et al. (1995) 
and Murnane et al. (1997).
Fresh, non-perfused cortical tissue was homogenized in ddH2O and exposed to 3 freeze-
thaw cycles using a methanol dry ice bath and a 37 °C water bath to lyse cells. Samples were 
centrifuged at 12,000 rpm for 40 min to pellet insoluble material. A Bradford protein assay 
(BioRad, Hercules, CA) was used to quantify the amount of protein in the supernatant and 
1000 μg of total protein of each sample was incubated with gelatin sepharose beads (GE 
HealthCare, Piscataway, NJ) to isolate gelatinases. Gelatinases were bound to the beads, 
washed and eluted from the beads using 20 mM phosphate buffer +10% DMSO. Isolated 
gelatinase samples were mixed with non-reducing 2× SDS loading sample buffer 
(Invitrogen, Carlsbad, CA), allowed to sit at room temperature for 5 min, and equal volumes 
were loaded into wells of Novex 10% Gelatin Zymogram gel (Invitrogen).
Following electrophoresis at 4 °C, the gel was removed, washed with 2.5% Triton 2 times, 
each for 30 min, and rinsed with ddH2O 2 times, each for 15 min, all at 4 °C. The enzymes 
embedded in the gel were then activated by incubating the gel in a developing solution 
consisting of 50 mM Tris-HCl, pH 7.5; 5 mM CaCl2; 0.15 M NaCl; 1 μM ZnCl2; and 0.02% 
NaN3 for ~72 h at 37 °C. The gel was stained with a 1% Amido Black solution in 50% 
MeOH+10% acetic acid for 10 min and de-stained in a 50% MeOH+10% acetic acid 
solution, until bands of clearing were observed. Areas of clearing indicated active 
gelatinases in the gel. A digital camera was used to capture images of gels and the areas of 
clearing at 95 and 92 kDa, that of pro-MMP-9 and active MMP-9, respectively, were 
quantified using Multi Gauge software (FujiFilm Corp. Life Science Division, Tokyo, 
Japan).
2.8. Statistical analysis
Statistical analysis was performed using Sigma Plot 11. Plasma ammonia, occludin and 
claudin-5 protein expression, FITC-dextran extravasation and MMP-9 activation were 
analyzed using a two-way ANOVA, followed by Tukey's post-hoc analysis. Body 
temperatures were analyzed using a two-way analysis of variance (ANOVA) with repeated 
measures, followed by Tukey's post hoc analysis. For all experiments, statistical significance 
was set at p < 0.05.
3. Results
3.1. Effects of lactulose on Meth-induced increases in plasma ammonia
Fig. 1 illustrates the concentrations of ammonia measured in plasma 2 h after the last Meth 
or saline injection. Meth significantly increased plasma ammonia by 48 ± 6%, compared to 
Vehicle Saline controls. There was no observed increase in plasma ammonia in Meth treated 
rats that were pretreated with lactulose. These effects were revealed by a significant two-way 
interaction between Meth and lactulose (F1,28 = 17.033, p < 0.001), a significant main effect 
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of Meth (F1,28 = 17.275, p < 0.001) and main effect of lactulose treatment (F1,28 = 15.614, p 
< 0.001). Post-hoc analysis revealed a significant difference between Vehicle Saline and 
Vehicle Meth (q = 8.283, p < 0.001) as well as Vehicle Meth and Lactulose Meth (q = 8.079, 
p < 0.001).
3.2. Effects of lactulose on Meth-induced alterations of BBB tight junction proteins
Fig. 2a illustrates the quantification of occludin protein expression in isolated capillaries, 24 
h after treatment with Meth or saline in lactulose or vehicle pretreated rats. Fig. 2c is a 
representative Western Blot image of occludin (57 kDa) and the loading control, α-tubulin 
(50 kDa) throughout a range of molecular weights to assess the specificity of the antibodies 
to occludin and claudin. Meth significantly decreased protein expression of occludin in 
isolated capillaries by 52 ± 9%, compared to Vehicle Saline controls. Occludin protein 
expression was not reduced in Meth treated rats that were pretreated with lactulose. These 
effects were revealed by a significant two-way interaction between Meth and lactulose (F1,36 
= 5.072, p < 0.05), a significant main effect of Meth (F1,36 = 4.833, p < 0.05) and main 
effect of lactulose treatment (F1,36 = 5.051, p < 0.05). Post-hoc analysis revealed a 
significant difference between Vehicle Saline and Vehicle Meth (q = 4.724, p < 0.01) as well 
as Vehicle Meth and Lactulose Meth (q = 5.260, p < 0.001).
Fig. 2b illustrates the quantification of claudin-5 protein expression in isolated capillaries 
and Fig. 2c is a representative Western Blot image of claudin-5 (22 kDa) and the loading 
control, α-tubulin (50 kDa). Meth significantly decreased protein expression of claudin-5 in 
isolated capillaries by 51 ± 9%, compared to Vehicle Saline controls. Claudin-5 protein 
expression was not reduced in Meth treated rats that were pretreated with lactulose. These 
effects were revealed by a significant two-way interaction between Meth and lactulose (F1,36 
= 6.468, p < 0.05), a significant main effect of Meth (F1,36 = 4.783, p < 0.05) and main 
effect of lactulose treatment (F1,36 = 4.683, p < 0.05). Post-hoc analysis revealed a 
significant difference between Vehicle Saline and Vehicle Meth (q = 5.020, p < 0.001) as 
well as Vehicle Meth and Lactulose Meth (q = 5.503, p < 0.001).
3.3. Effects of lactulose on Meth-induced increases in FITC-dextran extravasation
FITC-dextran extravasation was used as a measure of BBB permeability. Fig. 3A are 
representative images of cortical slices taken from rats perfused with FITC labeled dextran. 
While the saline treated groups as well as the Lactulose Meth treated group had distinct, 
brightly green stained capillaries against a black background, the Vehicle Meth treatment 
resulted in a brighter green fluorescence in tissue surrounding and between the capillaries.
FITC-dextran extravasation in images from the cortex was quantified and is illustrated in 
Fig. 3B. Meth increased FITC-dextran extravasation by 113 ± 24% in the cortex, compared 
to the Vehicle Saline control group. However, the Lactulose Meth treated rats did not have 
increased FITC dextran extravasation. A two-way ANOVA revealed a significant interaction 
of Meth and lactulose treatment (F1,13 = 7.159, p < 0.05). Post-hoc analysis revealed a 
significant difference between Vehicle Saline and Vehicle Meth (q = 4.637, p < 0.01) as well 
as Vehicle Meth and Lactulose Meth (q = 4.088, p < 0.05).
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In order to validate the FITC-dextran experiments, brain areas lacking a BBB, such as the 
hypothalamus were evaluated. The hypothalamus had more FITC-dextran extravasation than 
brain regions that have a functional BBB, such as the cortex, hippocampus and striatum of 
control rats (data not shown). Furthermore, it is important to note that the effects of Meth 
and lactulose on FITC-dextran extravasation are not brain region specific. Similar effects 
were observed in various regions of the cortex as well as the hippocampus and striatum (data 
not shown).
3.4. Effects of lactulose on Meth-induced hyperthermia
The effects of Meth and lactulose treatment on body temperatures are illustrated in Fig. 4. 
When body temperatures were measured 1 h after each Meth or saline injection, Meth 
administration (10 mg/kg ip, q 2 h ×4) produced an increase in core body temperatures of 
~2.75 °C, compared to Saline controls. Lactulose pretreatment did not have any effect on 
body temperatures in any group at any time point. A two-way repeated measures ANOVA, 
revealed a significant effect of treatment over time (F12,144 = 13.305, p < 0.001). Post-hoc 
analysis indicated that Vehicle Meth treated rats were significantly different from Vehicle 
Saline at 1 h (q = 11.706, p < 0.001), 3 h (q = 12.647, p < 0.001), 5 h (q = 12.879, p < 0.001) 
and 7 h (q = 15.284, p < 0.001) after the first Meth injection. In addition, Lactulose Meth 
treated rats were significantly different from Lactulose Saline treated rats at 1 h (q = 10.644, 
p < 0.001), 3 h (q = 12.354, p < 0.001), 5 h (q = 13.804, p < 0.001) and 7 h (q = 12.860, p < 
0.001) after the first Meth injection. Furthermore, Lactulose Meth did not differ from 
Vehicle Meth and Lactulose Saline did not differ from Vehicle Saline at any time point.
3.5. Effects of lactulose on Meth-induced increases in the ratio of active to pro-MMP-9
The effects of Meth and lactulose treatment on active and pro-MMP-9 in cortical brain 
tissue, 2 h after Meth or saline treatment, are quantified in Fig. 5A. Fig. 5B is a 
representative zymography image illustrating active MMP-9 (95 kDa) and pro-MMP-9 (98 
kDa). Meth and saline treatment in lactulose treated rats did not alter the ratio of active to 
pro-MMP-9, compared to Vehicle Saline controls. However, Meth treatment in Vehicle 
treated rats produced an increase in the ratio of active to pro-MMP-9 in the cortex by 45 
± 9%, compared to Vehicle Saline controls. These effects were revealed by a significant 
effect of lactulose (F1,28 = 10.975, p < 0.05). In order to investigate whether this effect was 
due to saline or Meth treatment, post-hoc analyses were run and revealed a significant 
difference between Vehicle Saline and Vehicle Meth (q = 3.557, p < 0.05) as well as Vehicle 
Meth and Lactulose Meth (q = 4.929, p < 0.01).
4. Discussion
The role of Meth-induced increases in plasma ammonia in Meth-induced BBB disruption 
was investigated. Meth-induced increases in plasma ammonia were blocked by lactulose and 
lactulose also prevented the disruption of BBB structure and function observed after Meth 
exposure. The prevention of Meth-induced BBB disruption by lactulose was associated with 
decreased activation of MMP-9, but not alterations in body temperature.
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Meth increased plasma concentrations of ammonia at 2 h after treatment (Fig 1), which is 
consistent with our previous findings and the observations that Meth produces liver damage, 
as indicated by liver histology and elevated levels of liver enzymes AST and ALT in the 
blood (Halpin and Yamamoto, 2012). It is believed that this liver damage contributes to 
Meth-induced increases in plasma ammonia as a result of decreased ammonia metabolism 
by the liver (Butterworth et al., 1987), but increases in plasma ammonia could also result 
from excess muscle activity and kidney damage (Dudley et al., 1983; Weiner and Verlander, 
2013). While Meth produced a 48% increase in plasma ammonia, this increase was 
associated with an approximate 400% increase in the concentration of brain ammonia 
(Halpin and Yamamoto, 2012). Furthermore, lactulose, which enhances ammonia excretion 
and attenuates the increases in plasma ammonia and the neurological symptoms of hepatic 
encephalopathy (Jia and Zhang, 2005; Nicaise et al., 2008; Al Sibae and McGuire, 2009), 
also prevented the Meth-induced increases in plasma ammonia (Fig 1; Halpin and 
Yamamoto, 2012). In addition, lactulose treatment blocked Meth-induced increases in brain 
ammonia concentrations. Based on these findings and the current results, lactulose was used 
as an effective tool to investigate the role of ammonia in Meth-induced BBB disruption.
Meth decreased protein immunoreactivity of the BBB structural tight junction proteins, 
occludin and claudin-5, 24 h after exposure to Meth (Fig 2). The decreases in BBB structural 
proteins were paralleled by an increase in extravasation of 10,000 Da FITC-dextran, 24 h 
after Meth treatment (Fig 3). This increase in FITC-dextran extravasation into the brain 
suggests an increase in BBB permeability, which is likely a result of the decreased 
expression of BBB structural proteins in the brain microvascular endothelial cells. However, 
it is important to note that structures other than those of the endothelial cells may be 
contributing to the increase in permeability since astrocytic endfeet and pericytes play a 
prominent role in maintaining proper BBB integrity and function (for review, see Abbott, 
2000; Winkler et al., 2011). Regardless, these data illustrate that Meth disrupts both the 
structure and function of the BBB and supports previous findings of Meth-induced 
permeability of the BBB to Evan's blue, FITC-albumin and endogenous IgG or albumin in 
the hippocampus, cortex, amygdala and striatum (Bowyer and Ali, 2006; Kiyatkin et al., 
2007; Kousik et al., 2011; Martins et al., 2011). Furthermore, Meth has been shown to 
decrease tight junction proteins, ZO-1, occludin and claudin-5, in the hippocampus of mice 
(Martins et al., 2011).
In contrast to the brain region-dependent effect of Meth on neurotransmitter systems, 
previous studies of Meth have shown that the disruption of the BBB is not limited to specific 
brain regions but occurs across numerous regions including the hippocampus, cortex, 
amygdala and striatum. These findings suggest a more global mechanism, possibly one 
initiated in the periphery that would affect all capillaries in the brain. The current results 
illustrate the protective effects of lactulose on Meth-induced BBB disruption and reflect 
such a global or more systemic mechanism of action. Lactulose is a non-digestible sugar that 
promotes ammonia excretion by using gut flora to acidify the intestinal lumen, converting 
ammonia to ammonium and trapping the ammonium within the lumen of the intestine. 
Lactulose is a large sugar molecule that is restricted to the lumen of the intestine and 
therefore, should not have direct effects on the brain. Lactulose not only prevented Meth-
induced increases in plasma ammonia (Fig 1) but also prevented decreases in BBB structural 
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proteins and increases in extravasation of 10,000 Da FITC-dextran (Figs. 2 and 3). It is 
possible that lactulose does not completely prevent increases in BBB permeability, in that 
molecules smaller than 10,000 Da may still be able to access the brain; however, the finding 
that lactulose prevents Meth-induced decreases in BBB structural proteins suggests that 
Meth-induced plasma ammonia is responsible for Meth-induced increases in BBB 
permeability to both large and small molecules. Furthermore, in models of hepatic 
encephalopathy in which plasma ammonia concentrations are also high, increases in BBB 
permeability have been observed. For example, in rodent models of acute liver failure, 
increased extravasation of HRP or Trypan blue into the brain have been observed (Ott and 
Larsen, 2004; Cauli et al., 2011). These previous studies have indirectly associated plasma 
ammonia with increased BBB permeability; however, the results presented here are the first 
to relate plasma ammonia increases to Meth-induced BBB disruption and provide a novel 
peripherally mediated mechanism by which Meth produces BBB damage.
Meth-induced hyperthermia was suggested to contribute to Meth-induced increases in BBB 
permeability since the extent of BBB disruption correlated with the extent of hyperthermia 
(Bowyer and Ali, 2006; Kiyatkin et al., 2007). These findings are consistent with the current 
results since Meth-induced hyperthermia is associated with increased plasma ammonia. 
Previous studies illustrate that prevention of Meth-induced hyperthermia prevents increases 
in plasma ammonia in Meth treated rats, likely a result of the attenuation of liver damage 
(Halpin et al., 2013). The current results would suggest that while Meth-induced BBB 
disruption and increases in plasma ammonia may be associated with hyperthermia, 
hyperthermia does not cause significant Meth-induced BBB disruption independent of 
ammonia, since lactulose did not affect body temperature (Fig 4). Therefore, it appears that 
Meth-induced BBB disruption mediated by ammonia may be independent of body 
temperature and that elevated ammonia may, in fact, serve as a key downstream mediator of 
the effects of hyperthermia on BBB disruption.
The role of oxidative stress in Meth-induced BBB disruption has also been suggested. 
Treatment with the antioxidant, Trolox, reduces Meth-induced decreases in TEER in brain 
microvascular endothelial cells in culture as well as extravasation of sodium-fluorescein in 
mice after Meth exposure (Ramirez et al., 2009). Similarly, inhibition of endothelial nitric 
oxide synthase (eNOS) prevents Meth-induced increases in vesicular transport of HRP and 
lymphocyte migration across the artificial barrier formed by cultured rat primary brain 
microvascular endothelial cells, but this movement of molecules and cells did not occur 
concurrently with a decrease in TEER (Martins et al., 2013). While oxidative stress has been 
shown to be a consequence of Meth exposure, oxidative stress also occurs in response to 
increases in ammonia. Excess ammonia can result in increased nitric oxide and superoxide 
production as well as a decrease in antioxidant enzymes in the brain (Kosenko et al., 1997a, 
1997b). Therefore, targeting increases in Meth-induced plasma ammonia likely attenuates 
Meth-induced oxidative stress as well as Meth-induced BBB disruption.
Meth-induced increases in ammonia also contribute to other processes known to disrupt the 
BBB such as increases in extracellular glutamate within the striatum (Halpin et al., 2014). 
Excess glutamate contributes to both oxidative stress and neuroinflammation (Siman and 
Noszek, 1988; Izumi et al., 1992; Nair and Bonneau, 2006; Wu et al., 2009) and 
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consequently, ammonia may well contribute to Meth-induced oxidative stress and 
neuroinflammation. In fact, lactulose prevents Meth-induced increases in GFAP, a marker of 
astrocytes (Halpin et al., 2014). Furthermore, the barrier properties of cultured endothelial 
cells were reduced as a result of activation of the TNFα/NFκB signaling pathway when the 
endothelial cells were exposed to Meth or exposed to conditioned medium obtained from 
astrocytes previously exposed to METH (Coelho-Santos et al., 2015). Moreover, ammonia 
produces neuroinflammation similar to that observed after Meth, such as microglial and 
astrocytic activation, increases in proinflammatory cytokines and cyclooxygenase (Thomas 
and Kuhn, 2005; Loftis et al., 2011; Bemeur and Butterworth, 2013). Therefore, although 
ammonia is likely not the sole contributor to the BBB disruption as METH also has direct 
effects on endothelial cells (Coelho-Santos et al., 2015; Martins et al., 2013), targeting 
increases in Meth-induced plasma ammonia may attenuate Meth-induced 
neuroinflammation and BBB disruption.
A way that ammonia dependent oxidative stress and inflammation converge to produce BBB 
disruption is through production and activation of MMPs, proteases that breakdown proteins 
of the extracellular matrix to breakdown the BBB (Mun-Bryce and Rosenberg, 1998; Yang 
et al., 2007). In fact, Meth produced an increase in the ratio of active to pro-MMP-9, 
indicating an increase in activation of MMP-9, which was prevented by lactulose treatment 
(Fig 5). Oxidative stress and inflammation are known to increase pro-MMP-9 at the 
transcriptional level and/or processing of pro-MMP-9 to active MMP-9 (for review, see 
Chakraborti et al., 2003). Although we did not observe an increase in total MMP-9 protein 
after Meth (data not shown), there was a change in the active state of MMP-9 in a manner 
prevented by lactulose. This suggests that ammonia plays a role in the activation of MMP-9 
but not in the transcription or translation of the MMP-9 gene. Activation of MMP-9 is a 
result of s-nitrosylation and subsequent cleavage of pro-MMP-9 to active MMP-9 (Gu et al., 
2002). Along these lines, ammonia likely mediates the nitrosylation of pro-MMP-9 through 
oxidative stress, glutamate and neuroinflammation, all of which can increase nitric oxide and 
subsequent nitrosylation of proteins (Dawson et al., 1991; Molina-Holgado et al., 2000; 
Obata, 2002; Baltrons et al., 2003). Therefore, it is likely that ammonia damages the BBB 
indirectly through increases in oxidative stress, glutamate, inflammation, and subsequent 
MMP-9 activation to cleave structural proteins of the BBB.
Taken together, the current results indicate a new mechanism by which Meth disrupts the 
BBB in a manner that is mediated by plasma ammonia. Moreover, this mechanism of BBB 
disruption is the first to report a peripheral contribution to Meth-induced BBB disruption, 
suggesting that identification of therapies designed to treat Meth-induced BBB disruption 
should look beyond those which target central mechanisms. Furthermore, ammonia-
mediated disruption of the BBB should be considered for other conditions that result in 
increased plasma ammonia, such as acute liver failure, kidney damage, chronic alcoholism 
and rhabdomyolysis.
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Fig. 1. Lactulose prevents Meth-induced increases in plasma ammonia 2 h after Meth treatment
Rats were pretreated with lactulose or vehicle for 2 days before treatment with Meth or 
saline. Ammonia was measured in plasma samples collected 2 h after the last Meth or saline 
injection. Meth treatment significantly increased plasma ammonia concentrations, which 
were blocked by lactulose pretreatment (*, p < 0.001, compared to Vehicle Saline; #, p < 
0.001, compared to Vehicle Meth) (n = 8 per group).
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Fig. 2. Lactulose prevents Meth-induced decreases in tight junction proteins of the BBB
Rats were pretreated with lactulose or vehicle for 2 days before treatment with Meth or 
saline. A) Occludin and B) claudin-5 were measured via Western Blot in isolated capillaries 
from cortical tissue, 24 h after Meth or saline treatment. Meth treatment significantly 
decreased occludin (*, p < 0.005, compared to Vehicle Saline) and claudin-5 (*, p < 0.001, 
compared to Vehicle Saline) protein expression, which was blocked by lactulose 
pretreatment (#, p < 0.001, compared to Vehicle Meth) (n = 6–13 per group). C) 
Representative Western Blot image of occludin, claudin-5 and α-tubulin.
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Fig. 3. Lactulose prevents Meth-induced increases in FITC-dextran extravasation
Rats were pretreated with lactulose or vehicle for 2 days before treatment with Meth or 
saline. Rats were intracardially perfused with 10,000 Da FITC-dextran, 24 h after Meth or 
saline treatment. A) Representative 20X confocal images of FITC-dextran in cortical 
sections. B) Quantification of FITC-dextran indicates that Meth treatment significantly 
increased FITC-dextran extravasation (*, p < 0.05, compared to Vehicle Saline), which was 
blocked by lactulose pretreatment (#, p < 0.05, compared to Vehicle Meth) (n = 4–5 per 
group).
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Fig. 4. Lactulose has no effect on Meth-induced hyperthermia
Rats were pretreated with lactulose or vehicle for 2 days before treatment with Meth or 
saline. During Meth or saline treatments, body temperatures were recorded via subcutaneous 
transponders. Meth significantly increased body temperatures over the treatment period (*, p 
< 0.001, Meth treated rats compared to saline treated rats) and lactulose had no effect on 
body temperatures. (n = 12–13 per group).
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Fig. 5. Lactulose prevents Meth-induced increases in activation of MMP-9
Rats were pretreated with lactulose or vehicle for 2 days before treatment with Meth or 
saline. Active and pro-MMP-9 were measured via gelatinase zymography in cortical 
homogenates 2 h after Meth or saline treatments. A) Meth significantly increased the ratio of 
active to pro-MMP-9 (*, p < 0.05, compared to Vehicle Saline), which was blocked by 
lactulose (#, p < 0.005, compared to Vehicle Meth). (n = 8 per group). B) Representative 
zymography images for active and pro-MMP-9 in cortical tissue.
Northrop et al. Page 20
Neuropharmacology. Author manuscript; available in PMC 2017 January 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
